» Articles » PMID: 28756693

Improved Hepatoprotective Activity of Silymarin Via Encapsulation in the Novel Vesicular Nanosystem Bilosomes

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2017 Aug 1
PMID 28756693
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

The main objective of the present work was to formulate, characterize, and evaluate silymarin (SM)-loaded bilosomes, compared to conventional liposomes, aiming at increasing the hepatoprotective activity of the drug. SM-loaded bilosomes were prepared by thin film hydration technique employing soybean phosphatidyl choline (SPC) and different bile salts. After being subjected to different methods of characterization, SM-loaded bilosomes were investigated for their hepatoprotective activity, in CCl hepatointoxicated rat model. The developed SM dispersions exhibited an entrapment efficiency ranging from 21.80 ± 2.01 to 84.54 ± 2.51% and a particle size diameter in the nanometric dimensions (413 ± 96.9 to 686.9 ± 62.38 nm), with a negative zeta potential values (<-45 mV). In vitro release study revealed a lower cumulative amount of drug released from the developed formulae, compared to free drug. Ex vivo intestinal uptake study, performed using confocal laser scanning calorimetry, revealed the superiority of bilosomal uptake compared to that of liposomes. In vivo studies revealed an enhanced hepatoprotective effect of SM-loaded bilosomes/liposomes compared to free drug. These results were in good correlation with histopathological examination. These findings support the potential use of bilosomes for improving the hepatoprotective activity of SM via oral administration.

Citing Articles

The Pharmaceutical and Pharmacological Potential Applications of Bilosomes as Nanocarriers for Drug Delivery.

Mitrovic D, Zaklan D, danic M, Stanimirov B, Stankov K, Al-Salami H Molecules. 2025; 30(5).

PMID: 40076403 PMC: 11901966. DOI: 10.3390/molecules30051181.


Development of biomaterials for bone tissue engineering based on bile acids.

Liu Y, Liu X, Liu C, Zhang W, Shi T, Liu G J Mater Sci Mater Med. 2025; 36(1):11.

PMID: 39812871 PMC: 11735600. DOI: 10.1007/s10856-024-06850-7.


Emerging Trends in Bilosomes as Therapeutic Drug Delivery Systems.

Kaurav H, Tripathi M, Kaur S, Bansal A, Kapoor D, Sheth S Pharmaceutics. 2024; 16(6).

PMID: 38931820 PMC: 11206586. DOI: 10.3390/pharmaceutics16060697.


Non-invasive caffeinated-nanovesicles as adipocytes-targeted therapy for cellulite and localized fats.

Khalil L, El-Refaie W, Elnaggar Y, Abdelkader H, Al Fatease A, Abdallah O Int J Pharm X. 2024; 7:100236.

PMID: 38524143 PMC: 10958479. DOI: 10.1016/j.ijpx.2024.100236.


Enhanced Oral Bioavailability of Progesterone in Bilosome Formulation: Fabrication, Statistical Optimization, and Pharmacokinetic Study.

Maheshwari R, Bhatt L, Wairkar S AAPS PharmSciTech. 2024; 25(2):29.

PMID: 38302633 DOI: 10.1208/s12249-024-02747-4.